Skip to main content

Drug Interactions between methoxyflurane and tigecycline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

methoxyflurane tigecycline

Applies to: methoxyflurane and tigecycline

GENERALLY AVOID: Coadministration of methoxyflurane with tetracycline antibiotics may result in enhanced renal toxicity. These agents have each been individually associated with rises in blood urea nitrogen (BUN) and serum creatinine, so concurrent use could lead to additive nephrotoxicity. There are case reports of fatal renal toxicity occurring in patients who received concurrent treatment with tetracycline and methoxyflurane.

MANAGEMENT: The manufacturer recommends avoiding the combination of methoxyflurane and antibiotics with known nephrotoxic potential, such as tetracyclines.

References (8)
  1. Kuzucu EY (1970) "Methoxyflurane, tetracycline, and renal failure." JAMA, 211, p. 1162-4
  2. Cousins MJ, Mazze RI (1973) "Methoxyfluranne nephrotoxicity. A study of dose response in man." JAMA, 225, p. 1611-6
  3. Albers DD, Leverett CL, Sandin JH (1971) "Renal failure following prostatovesiculectomy related to methoxyflurane anesthesia and tetracycline-complicated by candida infection." J Urol, 106, p. 348-50
  4. Proctor EA, Barton FL (1971) "Polyuric acute renal failure after methoxyflurane and tetracycline." Br Med J, 4, p. 661-2
  5. (2001) "Product Information. Declomycin (demeclocycline)." Lederle Laboratories
  6. (2022) "Product Information. Penthrox (methoxyflurane)." Medical Developments International Limited
  7. (2023) "Product Information. Penthrox (methoxyflurane)." Galen Ltd
  8. (2023) "Product Information. Penthrox (methoxyflurane)." Medical Developments International Limited

Drug and food interactions

Moderate

methoxyflurane food

Applies to: methoxyflurane

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (5)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  4. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  5. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer